Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | The importance of using MRD to guide treatment decisions in ALL

Caner Saygin • 7 Sep 2023
SOHO 2023
Acute Lymphoblastic Leukemia Leukemia

In this video, Caner Saygin, MD, University of Chicago, Chicago, IL, comments on using measurable residual disease (MRD) detection to guide treatment decisions in acute lymphoblastic leukemia (ALL) using both flow-based and next-generation sequencing (NGS)-based assays. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Caner Saygin

1:40
Challenges that remain in treating older patients with ALL
Caner Saygin • 19 Feb 2024
3:39
Outcomes of ALL stratified by socioeconomic factors
Caner Saygin • 19 Feb 2024
4:20
Therapy-related ALL: etiology, prognosis, and treatment
Caner Saygin • 19 Jan 2024
3:50
The impact of clonal hematopoiesis on outcomes of ALL
Caner Saygin • 19 Feb 2024

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals